New contract extends the partnership between the Danish biotech company and Lonza
Render of Ibex Solutions buildings currently under construction in Visp
Biotech company Genmab has extended its partnership with Swiss CDMO Lonza to cover preclinical and clinical development and manufacturing for a significant portion of its pipeline.
"Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years," said Karen Fallen, Head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech. "Genmab’s extensive pipeline is an opportunity for Lonza to combine the speed and flexibility of its Ibex Solutions with the know-how needed to manufacture pioneering molecular formats," she added.
A Danish company, Genmab specialises in antibody therapeutics, and have worked with the Swiss CDMO on multiple antibody-based programmes since 2002.
As part of the new agreement, Genmab becomes one of the first clients choosing the integrated package offered by Ibex Solutions, after Alector.
Lonza claims its Ibex Solutions in Visp is designed to provide Genmab with the flexibility and speed the company needs to take its candidates towards IND and commercialisation.
Ibex Design offers companies to take its candidates from gene to IND in 12 months and then move to reserved manufacturing capacity in Ibex Develop for clinical manufacturing and BLA submission when they need it.
Lonza said the agreement with Genmab aims to provide the biotech client with the security of supply and to enable Genmab to move rapidly into clinical manufacturing with the flexibility needed to manage an extensive pipeline through the demands of clinical trials.
The new agreement will cover development and clinical manufacturing of drug substance and drug product for certain programmes in Genmab’s pre-clinical and clinical pipeline. These include more complex molecular formats developed using Genmab’s DuoBody technology.